Club Biomed

We followed a company trying to bring a drug with similar indications for years, but it never made it to market.

F.D.A. Approves Addyi, a Libido Pill for Women The drug has faced criticism from those who say the F.D.A. was pressured. But advocates say the move was long overdue, given the options available to men.

We have been watching and wondering how long this would take. Now we know.

F.D.A. Approves Zarxio, First Biosimilar Drug The approval paves the way for alternatives to an entire class of complex and costly drugs to go on the market.

Happy Holidays.

One of Biomed's original stocks.

Biogen Idec Inc. (BIIB) Is Soaring On Positive Alzheimer''s Study Results Biogen Idec Inc. (BIIB) Is Soaring On Positive Alzheimer's Study Results (RTTNews.com) - Biogen Idec Inc. (BIIB) announced interim phase 1b results

A new class of cholesterol drugs: I see many interesting developments.

Sanofi-Regeneron’s Amgen Drug Rival Cuts Cholesterol Sanofi and Regeneron Pharmaceuticals Inc.’s cholesterol drug cut levels of the heart disease-causing fat in four studies, and there are early indications it may prevent death and heart attack.

Will this anti-Ebola strategy work? An investment opportunity?

Drug Used for Ebola-Related Virus Shows Promise Researchers said the experimental treatment kept monkeys alive in a study even after the Marburg virus was already detectable in the animals’ blood.

“Politicians are a lot like diapers. They should be changed frequently — and for the same reasons.” — Robin Williams as Tim Dobbs in “Man of the Year” (2006)

Interesting science? potential profits?

As Ebola’s Toll Rises, Drug Makers Race to Test Medicines Options include experimental treatments that have never before been tested on people and some of the world’s most widely used drugs.

Balancing risk and reward is a tricky proposition, whether it is a therapeutic or a recreational drug.

Pleasure Factor May Override New To***co Rules An economic analysis buried in regulations requires weighing public benefits against the happiness smokers might lose in quitting.

Anyone want to bet that this will be full immediately after it is opened?

Rejuvenated Harlem Building Becomes a Business Incubator for Biotechnology Providing start-up lab space, Harlem Biospace is an effort to tap the scientific talent and entrepreneurial spirit of Columbia University and City College.

The motley Fool on designer organisms.

How Designer Microbes and the Organism Industry Will Reshape Our World Many investors are captivated by the future of companies such as Tesla Motors and 3-D Systems -- and the potential creation of shareholder value on a scale that will be difficult to match. But are investors overlooking an even more promising industry with a brighter future? - Maxx Chatsko - Energy

Is Biomedical Reseach's future in Asia?
Thursday’s issue of the New England Journal of Medicine contained a perspective article, “Asia’s Ascent – Global Trends in Biomedical R&D Expenditures.” The authors conclude “…that U.S. inflation-adjusted R&D expenditures and the U.S. share of global expenditures decreased from 2007 through 2012…Moreover, the decline was driven almost entirely by reduced investment by industry, not the public sector, between 2007 and 2012. Sequestration of NIH funding in 2013 and beyond will exacerbate this reduction…” The authors also stated that the data “…suggests that industry is simply reallocating R&D funding to Asia-Oceania.”

Asia's Ascent — Global Trends in Biomedical R&D Expenditures — NEJM Perspective from The New England Journal of Medicine — Asia's Ascent — Global Trends in Biomedical R&D Expenditures